Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1384491 | 0.68 | GAA (0.32) | GAAMAPT | |
| SCHEMBL5321905 | 0.68 | CYP1A2 (0.30) | — | |
| SCHEMBL4792502 | 0.68 | ALOX15 (0.30) | ALOX15HSD17B10 | |
| SCHEMBL1162665 | 0.65 | GAA (0.37) | GAAMAPT | |
| SCHEMBL19679 | 0.64 | — | — | |
| SCHEMBL28212019 | 0.62 | ALOX15 (0.38) | GAAMAPTALOX15HSD17B10 | |
| SCHEMBL2514090 | 0.62 | GAA (0.50) | GAAMAPTALOX15 | |
| SCHEMBL3037604 | 0.62 | GAA (0.31) | GAA | |
| SCHEMBL313033 | 0.62 | — | — | |
| SCHEMBL21385505 | 0.62 | NOS2 (0.42) | GAAALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | claimed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | claimed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | claimed |
| EP-4392032-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME | Arena Pharmaceuticals, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-116917293-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116157154-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2023026185-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME | ARENA PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20200196602-A1 | HETEROARYLPHENYLAMINOQUINOLINES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | US | disclosed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| EP-1878720-A1 | Process for preparing chiral bicycloprolinates as intermediates for the preparation of peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1198231-A1 | BICYCLIC ANTAGONISTS SELECTIVE FOR THE(ALPHA)V(BETA)3 INTEGRIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001007036-A1 | BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200196602-A1 | HETEROARYLPHENYLAMINOQUINOLINES AND ANALOGUES | PIK3C3, DDT, CYP4X1 | GAA 102/4885MAPT 3159/4885ALOX15 3759/4885 |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | GAA 1023/4885MAPT 4717/4885ALOX15 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.